Table 1.

Numbers (percentages) of patients who reported adverse effects (AEs), severe AEs, bothering AEs, and AEs with impact on activities of daily living (ADL) at the 2nd day of an intravenous methylprednisolone (IVMP) treatment course, 1 day after the end of the treatment course, and 1 week after the end of the treatment course

	Day 2 IVMP (N = 59) (%)	1 day after IVMP (N = 58) (%)	1 week after IVMP (N = 56) (%)
No AE	13 (22)	4 (7)	16 (29)
One AE	13 (22)	8 (14)	14 (25)
Two or more AEs	33 (56)	46 (79)	26 (46)
Severe AE(s)	46 (30)	60 (29)	41 (33)
Bothering AE(s)	34 (22)	51 (25)	30 (24)
AE(s) with impact on ADL	39 (25)	69 (34)	51 (41)